Baas JM - Search Results

1

Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review.

Baas JM, Krens LL, Guchelaar HJ, Ouwerkerk J, de Jong FA, Lavrijsen AP, Gelderblom H. Baas JM, et al. Cancer Treat Rev. 2012 Aug;38(5):505-14. doi: 10.1016/j.ctrv.2011.09.004. Epub 2011 Nov 17. Cancer Treat Rev. 2012. PMID: 22100458 Review.

2

Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report.

Krens LL, Baas JM, de Jong FA, Guchelaar HJ, Gelderblom H. Krens LL, et al. Among authors: baas jm. Cancer Chemother Pharmacol. 2014 Feb;73(2):429-33. doi: 10.1007/s00280-013-2353-0. Epub 2013 Nov 21. Cancer Chemother Pharmacol. 2014. PMID: 24258455

3

Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.

Krens LL, Baas JM, Verboom MC, Paintaud G, Desvignes C, Guchelaar HJ, Gelderblom H. Krens LL, et al. Among authors: baas jm. Cancer Chemother Pharmacol. 2014 Jun;73(6):1303-6. doi: 10.1007/s00280-014-2462-4. Epub 2014 Apr 6. Cancer Chemother Pharmacol. 2014. PMID: 24705976 Free article.

4

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease.

Krens LL, Baas JM, Guchelaar HJ, Gelderblom H. Krens LL, et al. Among authors: baas jm. Cancer Chemother Pharmacol. 2018 Jan;81(1):179-182. doi: 10.1007/s00280-017-3479-2. Epub 2017 Nov 23. Cancer Chemother Pharmacol. 2018. PMID: 29170802 Free PMC article.

5

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.

Baas JM, Krens LL, Guchelaar HJ, Morreau H, Gelderblom H. Baas JM, et al. Oncologist. 2011;16(9):1239-49. doi: 10.1634/theoncologist.2011-0024. Epub 2011 Jul 8. Oncologist. 2011. PMID: 21742964 Free PMC article. Review.

6

Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.

Baas J, Krens L, Bohringer S, Mol L, Punt C, Guchelaar HJ, Gelderblom H. Baas J, et al. PLoS One. 2018 Dec 17;13(12):e0208080. doi: 10.1371/journal.pone.0208080. eCollection 2018. PLoS One. 2018. PMID: 30557370 Free PMC article.

7

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients.

Baas JM, Krens LL, ten Tije AJ, Erdkamp F, van Wezel T, Morreau H, Gelderblom H, Guchelaar HJ. Baas JM, et al. Invest New Drugs. 2015 Dec;33(6):1242-7. doi: 10.1007/s10637-015-0285-8. Epub 2015 Sep 19. Invest New Drugs. 2015. PMID: 26386973 Free PMC article. Clinical Trial.

8

Therapeutic modulation of k-ras signaling in colorectal cancer.

Krens LL, Baas JM, Gelderblom H, Guchelaar HJ. Krens LL, et al. Among authors: baas jm. Drug Discov Today. 2010 Jul;15(13-14):502-16. doi: 10.1016/j.drudis.2010.05.012. Epub 2010 Jun 2. Drug Discov Today. 2010. PMID: 20594936 Review.

9

Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study.

Krens LL, Simkens LH, Baas JM, Koomen ER, Gelderblom H, Punt CJ, Guchelaar HJ. Krens LL, et al. Among authors: baas jm. PLoS One. 2014 Nov 6;9(11):e112201. doi: 10.1371/journal.pone.0112201. eCollection 2014. PLoS One. 2014. PMID: 25375154 Free PMC article. Clinical Trial.

10

Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients.

Baas JM, Krens LL, Bos MM, Portielje JE, Batman E, van Wezel T, Morreau H, Guchelaar HJ, Gelderblom H. Baas JM, et al. Anticancer Drugs. 2015 Sep;26(8):872-7. doi: 10.1097/CAD.0000000000000255. Anticancer Drugs. 2015. PMID: 26053280 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters